Table 1.

Baseline characteristics of tumor, stratified by patient, treatment and response post-COVID-19 infection/vaccine

Case n°	Pathology	Patient age (years)/Sex	Treatment	Covid-19/ Vaccine	Follow-up	References
1	Classical hodgkin lymphoma	61/Male	No corticosteroid or immune-chemo-therapy was administered.	Covid-19	Four months after COVID-19 diagnosis: complete remission	[11]
2	Acute myeloid leukemia	57/Female	NO chemotherapy for AML. COVID-19 was treated with remdesivir at 200 mg intravenously (IV) on the first day, followed by 100 mg daily for 5 days and dexamethasone IV at 8 mg daily for 10 days. Trasfusion with six units of packed red blood cells and ten  units of platelets. Pirfenidone, colchicine (0.6 mg twice daily), and oxygen therapy	Covid-19	Six months after, diagnosis of COVID-19complete remission after 8 months later relapse	[12]
3	Acute myeloid leukemia	63/Female	Postpone treatment protocol. Supportive therapy only (Fluconazole 150 mg 3 times daily/Azithromycin 500 mg daily and Prednisone 100 mg for 5 days)	Covid-19	After 5 weeks from COVID-19 diagnosis remission and one year later no evidence of disease	[13]
4	T-ALL	28/Male	COVID-19 supportive treatment (Azithromycin 500 mg/day and Prednisone 40 mg daily for 5 days)	Covid-19	After 6 weeks diagnosis of COVID-19: no evidence of disease	[13]
5	Advanced follicular lymphoma	79/Female	Without lymphoma treatment	Covid-19	Nine months later diagnosis of COVID-19: complete remission	[14]
6	Follicular lymphoma	61/Male	NA	Covid-19	After 5 months from diagnosis of COVID-19: complete remission	[15]
7	Relapsed/refractory NK/T-cell lymphoma associated with Epstein-Barr virus (EBV) and autoimmune hemolytic anemia (AIHA)	20/Male	Red-blood cell transfusions and methylprednisolone at rate of 1 mg/kg of body weight per day were administered. No antiviral or cloroquine drugs were administered	Covid-19	Transient remission of NK lymphoma: remission during COVID-19 infection, followed after 1 month : lymphoma relapse.	[16]
8	Multiple myeloma	76/Female	A single dose of filgrastim, levofloxacin and acyclovir were administered. After the decreasing blood-oxygen levels, the patient was treated with dexamethasone and remdesivir.	Covid-19	During the next 2 months from COVID-19 diagnosis: no evidence of multiple myeloma	[17]
9	Chronic lymphocytic leukaemia (CLL)	67/Male	Asymptomatic untreated CLL. Multiple treatments including intravenous immunoglobulin and broad-spectrum antibiotics were used for febrile neutropenia	Covid-19	Complete remission after 12 months of follow-up after diagnosis of COVID-19	[18]
10	Metastatic renal cell carcinoma cancer (mCRC)	71/Male	Aside from supportive measures, no specific treatment for COVID-19 was administered.	Covid-19	Follow-up on 6 months from COVID-19 diagnosis: partial regression of metastatic lesions	[19]
11	Metastatic renal cell carcinoma cancer (mCRC)	58/Male	Antibiotics; firstly, clarithromycin and, subsequently, amoxycillin clavulanate for persistent fever. No antineoplastic treatment.	Covid-19	Four months later COVID-19 diagnosis: reduction in lung metastases	[19]
12	Metastatic colorectal cancer (mCRC)	65/Male	FU/FA/BEVA /depotentiated treatment, with the last cycle performed 1 month before COVID-19 infection	Covid-19	Follow-up at 18 months: from COVID-19 diagnosis complete response with regression of hepatic lesions	[20/21]
13	Metastatic colorectal cancer (mCRC)	58/Male	The patient refused post-operative chemotherapy.	Covid-19	Post COVID-19 infection: reduction of the liver metastatic lesion. Time to-Progression: 23 months	[20/21]
14	Metastatic colorectal cancer (mCRC)	60/Female	After six cycles with FOLFIRI/PANI, CT scan in September 2020 displayed disease stabilization	Covid-19	Progression of disease at 2 months from diagnosis of COVID-19	[21]
15	Primary cutaneous anaplastic large-cell lymphoma	57/Male	NA	COVID-19 vaccination (BionTech/Pfizer)	1 week before the second dose of COVID-19 vaccination: complete resolution of untreated lymphoma	[22]
16	Myoepithelial carcinoma of the left parotid and lung lesion	61/Female	Close surveillance.	Covid19 vaccination (mRNA-1273)	Persistent tumor shrinkage on follow-up of 9 months, after the second dose of the vaccine.	[23]